• Moderna recently presented at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, highlighting progress across its mRNA vaccine and oncology pipeline, including regulatory filings for its influenza vaccine and advances in its personalized cancer vaccine program with Merck.
• This combination of late-stage cancer vaccine data, broader infectious disease ambitions, and ongoing patent disputes with BioNTech is reshaping how investors assess the durability and breadth of Moderna’s mRNA platform.
• We’ll now examine how progress in Moderna’s personalized cancer vaccine program with Merck could influence the company’s broader investment narrative.

Find 44 companies with promising cash flow potential yet trading below their fair value.

Moderna Investment Narrative Recap

To own Moderna, you need to believe its mRNA platform can move beyond COVID seasonality into a broader, more durable portfolio, with oncology and respiratory vaccines offsetting current revenue volatility and ongoing losses. The Goldman Sachs presentation reinforces that story but does not fundamentally change the near term catalyst, which remains late stage cancer and flu readouts, or the biggest risk, which is that new vaccines and oncology programs may not scale quickly enough to smooth cash flows.

The most relevant recent update here is the progress in Moderna’s personalized cancer vaccine mRNA 4157 with Merck, which showed encouraging data in advanced melanoma when combined with Keytruda. This program now sits at the center of the “second act” narrative for Moderna, alongside efforts to secure approvals for its influenza vaccine after the FDA Refusal to File, and could be critical to reducing the company’s dependence on a still volatile COVID and RSV franchise.

But while the science story is compelling, investors should also be aware of how ongoing legal and patent disputes could still limit the ultimate payoff...

Moderna's narrative projects $3.2 billion revenue and $407.1 million earnings by 2029. This requires 17.9% yearly revenue growth and an earnings increase of about $3.2 billion from -$2.8 billion today.

Uncover how Moderna's forecasts yield a $46.10 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming only about 2.2 percent annual revenue growth and ongoing losses before this update, so if you are weighing the recent conference news against that more cautious view, it is worth recognizing how differently people can read the same data and exploring why those expectations may or may not still hold.

Explore 5 other fair value estimates on Moderna - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.